Image For Activity Cover
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity (JACC: CardioOncology State-of-the-Art Review March 2022-2)
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity JACC: CardioOncology State-of-the-Art Review
Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and targeted cancer therapies. Both general measures and specific pharmacologic cardioprotective interventions as well as imaging- and biomarker-based surveillance strategies to identify patients at high risk have been tested in randomized controlled trials to prevent or attenuate cancer therapy–related cardiotoxic effects. Although meta-analyses including early trials suggest an overall beneficial effect, there is substantial heterogeneity in results. Recent randomized controlled trials of neurohormonal inhibitors in patients receiving anthracyclines and/or human epidermal growth factor receptor 2–targeted therapies have shown a lower rate of cancer therapy–related cardiac dysfunction than previously reported and a modest or no sustained effect of the interventions. Data on preventive cardioprotective strategies for novel cancer drugs are lacking. Larger, prospective multicenter randomized clinical trials testing traditional and novel interventions are required to more accurately define the benefit of different cardioprotective strategies and to refine risk prediction and identify patients who are likely to benefit.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Torbjørn Omland, MD, PHD, MPH
Siri Lagethon Heck, MD, PHD
Geeta Gulati, MD, PHD

Important Dates

Date of Release: March 15, 2022     
Term of Approval/Date of CME/MOC/ECME Expiration: March 14, 2023 

Summary
Availability: On-Demand
Expires on Mar 14, 2023
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By